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The development of new nanoparticle formulations that are capable of high transfection 
efficiency without toxicity is essential to provide new tools for gene therapy. However, 
the issues of complex, poorly reproducible manufacturing methods, and low efficiencies 
during in vivo testing have prevented translation to the clinic. We have previously 
reported the use of cholesteryl oleate as a novel excipient for solid lipid nanoparticles 
(SLNs) for the development of highly efficient and nontoxic nucleic acid delivery 
carriers. Here, we performed an extensive characterization of this novel formulation to 
make the scale up under Good Manufacturing Practice (GMP) possible. We also describe 
the complete physicochemical and biological characterization of cholesteryl oleate-
loaded SLNs to ensure the reproducibility of this formula and the preservation of its 
characteristics before and after the lyophilization process. We defined the best 
manufacturing method and studied the influence of some parameters on the obtained 
nanoparticles using the Quality by Design (ICH Q8) guideline to obtain cholesteryl 
oleate-loaded SLNs that remain stable during storage and guarantee in vitro nucleic acid 
delivery efficacy. Our results indicate that this improved formulation is suitable for gene 
therapy with the possibility of scale-up the manufacturing of nanoparticles under GMP 
conditions. 
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The administration of DNA and RNA molecules to modulate the expression of proteins 
is a promising approach for the treatment of several human disorders such as cancer, 
cystic fibrosis and multiple sclerosis (Naldini, 2015). Nucleic acid-based therapies can 
replace mutated genes by gene replacement and increase or decrease protein function by 
gene overexpression or RNA interference (RNAi) gene suppression, respectively. Despite 
remarkable in vitro and in vivo results using nucleic acid delivery systems, the 
translational progress for medical applications has been limited mainly due to poor 
delivery efficiency and complex manufacturing methods. Addressing the barriers 
associated with delivery efficiency is a challenge that needs to be overcome for the 
clinical translation of nucleic acid-based systems. Although many approaches have been 
taken for the development of safe, reproducible, robust, and efficient new delivery 
systems, the percentage of success is limited, and additional research to meet the delivery, 
safety, and industry challenges is required (Wilhelm et al., 2016). The research and use 
of nanoparticles in the biomedical field as nonviral vectors for the delivery of nucleic 
acids has become very important in recent decades. Different types of nanoparticles can 
be engineered with distinctive materials, compositions, and physicochemical properties 
to enable the cellular uptake of biomolecules for a wide range of biological applications. 
Among nanoparticle-based methods, cationic solid lipid nanoparticles (cSLNs) are one 
of the most promising systems for gene therapy (del Pozo-Rodríguez et al., 2016) (Suñé-
Pou et al., 2017)(Nayerossadat et al., 2012). Several advantages have been associated 
with the use of cSLNs as carriers: i) good biocompatibility and low cytotoxicity 
(Dolatabadi et al., 2014) (Geszke-Moritz and Moritz, 2016); ii) the possibility of 
transfecting DNA and RNA in vitro and in vivo (De Jesus and Zuhorn, 2015); iii) the 
possibility of using different administration routes, such as intravenous, intramuscular, 
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oral, topical, nasal, pulmonary or ocular routes (Weber et al., 2014) (Apaolaza et al., 
2016) (Kang et al., 2018) (Zhao et al., 2018) (Ferreira et al., 2017) (Ren et al., 2013) 
(Alvarez-Trabado et al., 2017); iv) the capability to be functionalized to enhance 
therapeutic effects (Rostami et al., 2014); and v) the possibility of using safe, 
reproducible, and robust manufacturing methods (Müller et al., 2000). 
The cSLNs are spherical vesicles based on oil-in-water microemulsions and, generally 
consist of a lipid core and a surfactant that stabilizes the particle in an aqueous 
environment (Hou et al., 2003)(Kumar and Randhawa, 2013). The use of cationic lipids 
leads to a positive charge on the nanoparticle surface, which mediates the binding of 
nucleic acids for SLNplex formation. Compatibility among the excipients and the active 
biomolecules is of high importance and can greatly affect the particle size and zeta 
potential of nanoparticles and the stability of the formulation (Sznitowska et al., 2017) 
(Karn-orachai et al., 2016). Appropriate preformulation studies and the characterization 
of the final formulation are required to ensure good compatibility among the nanoparticle 
components and the adequate stability of the final product. Analogously, the cSLN 
manufacturing method is also of critical importance. Several different approaches have 
been developed to produce cSLNs with potential good therapeutic use; however, most of 
these nanoparticles are made in small batches using labor-intensive, time-consuming, and 
high-cost methods. While these engineered materials are adequate for early experimental 
studies, this limits the translation of promising nanomaterials to clinical applications, 
where scale-up, reliability, and cost-effective manufacturing to meet the Good 
Manufacturing Practice (GMP) and the International Council for Harmonization of 
Technical Requirements for Pharmaceuticals for Human Use (ICH) standards are 
required. The concept of the ICH Q8 guideline is based on defining a design space, which 
consists of evaluating the impact of material attributes and process parameters on 
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manufacturability and the critical quality attributes of final products (European Medicines 
Agency, 2015)(Huang et al., 2009). According to Quality by Design (QbD), the quality 
of a product must be “built into” the product and ensured since the design, through an 
extensive mechanistic understanding of the relations between the product quality and 
parameters, can have an impact on the quality (Tomba et al., 2013). 
We have recently proposed the use of a cholesterol derivative, cholesteryl oleate, in 
cSLN-nucleic acid formulations to improve the cytotoxicity and transfection efficiency 
as an avenue for the development of highly efficient and biocompatible carriers for 
therapeutic purposes (Suñé-pou et al., 2018). The present study conducted an extensive 
in vitro and in vivo characterization of this novel formulation to show its feasibility for 
successful manufacturing scale-up. The process described here establishes a reproducible 
and robust process for the synthesis of novel and stable cholesteryl oleate-loaded cSLNs 
that are suitable for manufacturing and comply with GMP guidelines for potential use in 
clinical applications. 
2. Materials and methods 
2.1. cSLN production 
The following materials were used to synthesize the nanoparticles: poloxamer 188 
(Sigma-Aldrich Co., St Louis, MO, USA), octadecylamine (Acros Organics, Geel, 
Belgium), stearic acid (EMD Millipore, Billerica, MA, USA), cholesteryl oleate (Alfa 
Aesar, Karlsruhe, Germany) and ultrapure water (EMD Millipore). 
The proportions of all components of the formulation were as follows: 200 mg of stearic 
acid, 300 mg of cholesteryl oleate, 600 mg of octadecylamine, and 100 mg of poloxamer 
188. The cSLNs were produced using the hot microemulsification method, as previously 
described (Fàbregas et al., 2014). First, all the components were heated and melted at 80 
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°C. In separate receptacles, we added the matrix lipids (stearic acid and cholesteryl 
oleate), the cationic lipid, the poloxamer 188, and 20 mL of Milli-Q water. When all 
components were melted and had reached the same temperature, the matrix lipids were 
poured into the second receptacle with stirring at 20.000 rpm (IKA® T-25 Digital Ultra-
Turrax®, S25N-8G rotor) for 10 min. The emulsion that was obtained was dispersed into 
125 mL of cooled water at 4 °C under the same stirring conditions. In this phase, 
nanoparticles were formed. This final nanoemulsion was centrifuged at 19,000 x g at 4 
°C for 30 min and then filtered through 43-48 µm filters (FILTER-LAB®, Filtros ANOIA, 
S.A. Barcelona). The final nanoparticle suspension was mixed with a solution of 5% 
trehalose to lyophilize it, to improve its stability and to preserve its properties during the 
lyophilization process using an L-3 Telstar (Spain) laboratory freeze dryer system. 
2.2 Improvement of the manufacturing method 
To improve the manufacturing method, several changes were introduced during different 
steps of the process by employing QbD methodologies. Risk assessment was used 
throughout development using the SMEA protocols to identify potentially high-risk 
formulation and process variables. A follow-up study of particle size and zeta potential 
was performed to evaluate the impact of these modifications on the final product. The 
main positive changes involved the temperature of the water to pour the first emulsion 
and temperature of the centrifugation step. 
2.3. Stability study 
Particle size and zeta potential values were determined when the suspension of 
nanoparticles was stored at 4, 25 and 37 °C. Similarly, particle size and zeta potential 
values were determined after the lyophilization process when the nanoparticles were 
stored at RT and 4 °C. 
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2.4. Physicochemical characterization of the cSLNs 
2.4.1. Determination of the particle size 
Particle size was determined by laser diffraction according to the Mie theory on a 
Mastersizer 2000 (Malvern Instruments, UK). All samples were measured in triplicate 
using a sufficient amount of sample to obtain an appropriate obscuration percentage. A 
Fourier transform was applied to the measured diffracted angles to obtain the particle size 
data using specialized software, and the mean value was calculated in nanometers (nm). 
2.4.2. Zeta potential 
A Zetasizer Nano Z (Malvern Instruments, UK) was used to determine the surface charge 
of the cSLNs by laser doppler microelectrophoresis. The samples were stabilized at 25 
°C prior to a measurement. The electrophoretic mobility between electrodes that were 
connected to the cell containing the sample was converted to zeta potential values using 
specific software. The results are expressed in mV. 
2.4.3. Transmission electron microscopy (TEM) 
The surface and content homogeneity of the cSLNs were analyzed by TEM using a Spirit 
120 kV microscope. 
2.4.4. X-ray photoelectron spectroscopy 
The surface nitrogen percentage in the cSLNs was quantified. X-ray photoelectron 
spectroscopy (XPS) experiments were performed using a PHI 5500 Multitechnique 
System (Physical Electronics) with a monochromatic X-ray source (aluminum K-alpha 
line of 1486.8 eV and 350 W) that was placed perpendicular to the analyzer axis and 
calibrated using the 3d5/2 line of Ag with a full width at a half maximum (FWHM) of 0.8 
eV. 
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The analyzed area was a circle with a 0.8 mm diameter, and the selected resolution for 
the general spectra was a pass energy of 187.5 eV and 0.8 eV/ste. For the spectra of the 
different elements in the depth profile spectra, the resolution was a pass energy of 23.5 
eV and 0.1 eV/step. A low energy electron gun (less than 103V) was used to discharge 
the surface when necessary. All measurements were made in an ultrahigh vacuum (UHV) 
chamber between 5 x 10-9 and 2 x 10-8 Torr. 
2.4.5. Differential scanning calorimetry (DSC) 
The possible interactions of the components in the formulation were assessed using DSC. 
DSC was performed in a DSC-822e (Mettler Toledo) at a heating rate of 10 °C/min over 
a range from 30 °C to 200 °C using the heat flow method. This DSC mode measures the 
difference in the temperature between pans and converts it into a heat flow signal after a 
calibration procedure. The samples were weighed into a 40 µl aluminum pan, and an 
empty pan was used as a reference. Dry nitrogen (50 ml/min) was used to perform the 
assay in a nonoxidative atmosphere.  
2.4.6. Eutectic point 
The eutectic point of the dispersion of the cSLNs and the cSLNs:Agarose was determined 
by DSC. DSC was performed by freezing the sample from 25 °C to -80 °C at 10 °C/min. 
The sample was kept at this temperature for 1 min and then heated to 25 °C at 10 °C/min. 
2.5. Biological characterization of cSLNs 
2.5.1. SLNplex formation (agarose gel) 
The analysis of SLNplex formation and loading efficiency of the cSLNs with plasmid 
DNA (pDNA) was performed by electrophoretic mobility of the samples on agarose gels. 
SLNplexes were prepared by mixing the cSLNs with the appropriate amount of pDNA. 
The mixture was kept at RT for 40-45 min to allow the complexes to form. An aliquot of 
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the mixture was loaded in the agarose gel. DNA mixed with Milli-Q water as a negative 
control. For electrophoretic separations in agarose gel, agarose D-1 at 0.8% in 1X Tris-
acetate-EDTA (TAE) (40 mM Tris-acetate, 1 mM EDTA) with RedSafe® as a nucleic 
acid staining solution was used. The 6x gel loading dye thas was used (NEB B7025S) 
comprised 2.5% Ficoll-400, 10 mM EDTA, 3.3 mM Tris-HCl (pH 8.0 @ 25 °C), 0.02% 
Dye 1 (pink/red) and 0.0008% Dye 2 (blue). Once resolved in agarose gels, sample 
visualization took place in a GelDoc® EZ Imager (BioRad®, USA) system using BioRad® 
ImageLab 5.2.1 software. 
2.5.2. Confocal microscopy and cell distribution of nanoparticles and SLNplexes 
To study the transfection efficiency, confocal microscopy studies were performed using 
HeLa cells. The cells were grown in 35-mm plates (Falcon) to a confluence of 60-70%. 
cSLNs and Cy3-labeled siRNA were mixed in a 1.5 ml tube as previously described for 
pDNA (see section 2.5.1) and added to every well. As a transfection control, Cy3-labeled 
siRNA (Sigma) was transfected into cells using Lipofectamine 2000. Cy3-labeled siRNA 
in water was used as a negative control. 
After one hour, the cells were harvested and prepared for confocal microscopy using a 
Leica SP5 spectral confocal laser scanning microscope. Images were analyzed and 
digitally processed for presentation using LAS AF v2.3.6 software and Adobe Photoshop 
CS3 Extended v10.0 software, respectively. 
3. Results 
3.1. Improvement of cSLN production 
We identified the temperature of the water that was used to pour the first emulsion as a 
critical quality attribute (CQA) for process validation using a QbD approach. We tested 
three different conditions: water at 4 °C (Suñé-pou et al., 2018), 25 °C and 37 °C. We 
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observed small difference in particle size at 4 °C, 25 °C or 37 °C. The smallest particle 
size was obtained at 37 °C with a value of approximately 170 nm (Figure 1). The 
specifications based on the analysis of the particle size distribution during the 
manufacturing process for this formula are set at 200 ± 50 nm, therefore, all the conditions 
tested resulted in an attainable particle size. Based on these data, the temperature of 25 
°C is suitable for the stirring in the tank and avoids to design controllers for temperature 
control in the stirred tank. This improved the manufacturing method and further 
established a working Design Space (DS) for this processing step according to the QbD 
criteria. 
We next assessed the temperature of the centrifugation process. Two conditions were 
tested: i) centrifugation at 4 °C and ii) centrifugation at RT. No differences were observed 
in terms of particle size (Table 1). This result avoids the necessity of cooling down the 
centrifuge and controlling the temperature, thus facilitating the manufacturing method. 
3.2. Studies of thermal stability 
We first tested the stability of freshly made cSLNs. We observed that storage conditions 
are important for nanoparticle preservation (Figure 2A). During the first 3 days, the 
particle size did not significantly change at 4 °C, 25 °C or 37 °C. On day 5, we observed 
the presence of aggregates at 25 °C, which was also observed on day 7 at 37 °C. The 
aggregation increased over time, reaching a particle size of approximately 10 µm on day 
15 at 25 °C and 37 °C. At 4 °C, the particle size of cSLNs did not change during this time 
period. We conclude that 4 °C is the most appropriate temperature for the storage of 
freshly made cSLNs. 
We next extended the incubation time at 4 °C and observed the formation of aggregates 
on day 18, which was maximized on day 24 (Figure 2B). This result prompted us to 
perform a stability study using lyophilization to preserve cSLN integrity. After 
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lyophilization, the nanoparticles were monitored at 4 °C and 25 °C, which are favorable 
temperature conditions for drug storage and maintenance. The particle sizes of these 
cSLNs were analyzed after resuspending with Milli-Q water after each time point. We 
did not observe a change in particle size as far as one year after the study, which 
demonstrates that the addition of the trehalose cryoprotectant to the cSLNs preserved 
efficacy, even when reconstituted in pure Milli-Q water (Figure 2C). 
3.3. Physicochemical characterization 
The particle size was determined several times, and a size of 207  ± 40 nm was achieved 
(Table 2). Furthermore, the presence of aggregates was not observed, demonstrating that 
centrifugation and filtration removed the possible aggregates present in the suspension 
after fabrication. 
For the zeta potential values, the cSLNs exhibited values between 30-40 mV, which are 
optimum to achieving a good positive surface that is effective for nucleic acid binding. It 
has been reported that values below 25 mV may present problems for the formation of 
SLNplexes and for the stability of nanoparticles (Honary and Zahir, 2013). 
The TEM images confirm the results obtained with the Mastersizer (Figure 3). The 
nanoparticles showed a spherical morphology and homogenous surfaces with particle 
sizes consistent with those determined previously. We did not observe the presence of 
aggregates in these images, supporting the stability of the resuspended lyophilized 
particles. 
Regarding the surface nitrogen percentage, the XPS results showed the presence of this 
atom in the nanoparticle surface (Figure 4 and Table 3). These data are relevant because, 
in the water suspension, this nitrogen will be protonated, thereby allowing the positive 
charge on the particle surface, which is responsible for the nucleic acid binding capacity. 
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The compatibility among the components in the formulation was assessed using DSC 
(Figure 5). The results indicate that there are no interactions among cholesteryl oleate, 
stearic acid, octadecylamine, and poloxamer 188. Binary mixtures between the 
components exhibited no exothermic peak, which indicates that there are no physical or 
chemical interactions and thus validates this formulation for further studies. 
The study of the eutectic point was carried out in a suspension of cSLNs and a mixture of 
cSLNs and 5% trehalose at a ratio of 1:1 (Figure 6). The results showed that the eutectic 
point of the cSLNs was lower than the eutectic point of the mixture (-16.69 °C versus -
29.98 °C). We tested several different cryoprotectants and trehalose was the only one 
capable of achieving cryopreservation while maintaining a good particle size after 
resuspension (data not shown). Nevertheless, the lyophilization process begins at 
temperatures of -40 °C; therefore, there is a margin of 10 °C to avoid boiling events. 
3.4. Biological characterization 
Gel electrophoresis retardation assays are widely used to assess the nucleic acid binding 
efficiency of cSLNs. The presence of unbound free DNA in the gels reflects the binding 
capacity of the nanoparticles (Figure 7). When the DNA amount was 0.5-1.0 µg, no free 
DNA was observed in the gel, which indicated that the DNA was completely bound to 
the cSLNs. When 2 µg of DNA was used, minimal free DNA was observed in the gel, 
and considerable free DNA was detected in the gel upon loading 5 µg of DNA. Our results 
confirmed the suitability of these cSLNs for DNA binding. 
Confocal microscopy was used to assess the transfection capacity and the cellular 
localization of cSLNs:RNA SLNplexes in HeLa cells using Cy3-labeled RNA. We 
observed minimal fluorescence when Cy3-labeled RNA alone was added to the cells 
(Figure 8A-B). Large and numerous foci were observed in the cytoplasm and nuclei of 
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cells transfected with the cSLN-Cy3-labeled RNA complexes (Figure 8C-D). These data 
demonstrate the capacity of this improved formulation to carry and deliver nucleic acids 
into the cytoplasm and nucleus of cells with high efficiency. 
4. Discussion 
The nanoformulation of medicinal drugs is of fundamental importance to address 
pharmaceutical and biopharmaceutical needs for the delivery of clinically relevant 
molecules. A complete understanding of nanoformulation requires attention to 
fundamental research to develop efficient carriers for drug delivery applications. For 
nanoparticles, a good knowledge of materials and fabrication approaches is essential for 
achieving optimal physicochemical and biological properties to overcome barriers in 
nanomedicine delivery. Precise, high-resolution nanoparticle characterization is also 
essential for nanoparticle submission, review, and acceptance of national and 
international regulatory agencies prior to commercialization. 
One of the purposes of this study was to optimize formulations of cholesteryl oleate-
loaded cSLNs and their fabrication methods to maximize therapeutic efficacy. Regarding 
the manufacturing process, we optimized nanoparticle synthesis by working on two 
critical steps of the protocol: the temperature of water when the first emulsion is poured 
and the temperature of centrifugation. Both improvements ease the manufacturing 
process and avoid temperature control during this process. These improvements are also 
a first step for a further QbD study to establishing a working DS in every step of the 
manufacturing process. Stability is a critical attribute that plays an important role in the 
drug development process. Nanoparticle stability must be determined in the formulation 
itself and for all the parameters involved with storage and shipment, such as heat and 
time, to produce a product that is safe and effective. A long-term stability study needs to 
be performed to evaluate the presence of degradation products that may potentially affect 
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storage and shipment conditions. Suboptimal storage conditions can affect nanoparticle 
properties and modulate toxicity and bioavailability (Izak-Nau et al., 2015). We 
performed this study with our formulation and obtained the following conclusions. 
Nanoparticle suspensions should be stored at 4 °C for the best performance for a 
maximum of 15 days. However, a lyophilization process must be carried out before these 
15 days. Indeed, the lyophilization conditions described here improved long-term stability 
at 25 °C, where nanoparticles were stable for at least 1 year. Nanoparticle preservation at 
room temperature overcomes obstacles to cold storage in many rural parts of developing 
countries, where a great number of the largest research-based pharmaceutical companies 
have increased efforts to provide access to essential medicines (Hogerzeil et al., 2014 
Lancet Glob Health 2014). 
As stated previously, the physicochemical properties of candidate nanoparticles must be 
characterized to achieve preferred conditions for maintaining low toxicity and good 
bioactivity. Particle size and zeta potential, which are indicative of the particle surface 
charge, provide useful information about the cellular uptake and toxicity of nanoparticles 
and are therefore widely used parameters for the validation of the nanoformulations. The 
working protocol that is described in this manuscript achieved good particle size and 
positive surface charge and were therefore suitable for further investigation. Spherical 
morphologies and homogenous surfaces of cSLNs were visible in TEM images that 
further confirmed our results of particle size using a Mastersizer. The positive charge of 
the surface that was observed in the zeta potential measurements is due to the surface 
nitrogen that is found in the formulation. This positive charge will allow SLNplexes to 
form. We also observed that all the excipients used in the formulation of the cSLNs 
showed no interactions among the components and, consequently, revealed a good 
compatibility (Figure 5). Finally, we optimized a lyophilization protocol for cSLNs 
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loaded with cholesteryl-oleate and compared the long-term stability of lyophilized 
nanoparticles under different storage conditions. For lyophilization to occur, the 
temperature of the frozen matrix must be maintained below the eutectic point of the 
formulation. The choice of the cryoprotectant is critical to preserving the properties of the 
nanoparticles after resuspension (Fonte et al., 2016). The addition of the trehalose 
cryoprotectant at 5% w/v in the formula decreased the eutectic point by 10 degrees (from 
-18 °C to -28 °C), which required the formula to reach temperatures of approximately -
40 °C to completely freeze the nanoparticle suspension. In these conditions, cSLNs 
maintained their physicochemical properties and transfection capacity over time. 
Functionalized nanoparticles have been used in biotechnology for nuclear transfection 
and targeting in nonviral gene delivery applications because they easily enter cells (Ku et 
al., 2014)(Rostami et al., 2014). However, these nanoparticles are expensive and have 
complicated procedures. The binding capacity and transfection efficiency results obtained 
with our optimized cSLN formulation validate the use of these nanoparticles as safe and 
effective carriers for nonviral nucleic acid delivery. Confocal microscopy images 
supported this statement, as they showed many intense siRNA-labeled fluorescent dots 
throughout the cytoplasm and cell nuclei, achieving a transfection efficiency of 
approximately 50%. These results encourage the use of these nanoparticles for further 
investigation. 
5. Conclusions 
The control of process parameters in nanoformulation is essential to achieve efficient, 
safe, stable, and reproducible formulations. Key synthesis parameters include 
temperature, mixing, concentrations, and reaction times. We hereby applied several 
approaches to address these issues and reported a complete characterization of an 
optimized formulation to produce nanoparticles with GMPs that remain stable during 
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storage and guarantee in vitro nucleic acid delivery efficacy. The improvement of this 
manufacturing method produced nanoparticles with substantially increased stability 
compared to nanoparticles obtained by a standard formulation strategy, encouraging their 
use for gene targeting applications. 
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Figure 1. Effect of the temperature of the solvent and stirring speed on the particle size.  
Figure 2. Thermal stability studies of nanoparticles. (A) Freshly made cSLNs were 
incubated at 4 °C, 25 °C or 37 °C, and particle size was measured at different time points 
(1-15 days). (B) The same experiment described in A was carried out at 4 °C for 24 days. 
(C) Lyophilized cSLNs were incubated at 4 °C and 25 °C for 1 year, and particle size was 
analyzed at different time points after resuspending the cSLNs in Milli-Q water. 
Figure 3. TEM image after the reconstitution of lyophilized cSLNs. 
Figure 4. XPS depth profile spectra of lyophilized cSLNs. 
Figure 5. DSC depth profiles of binary mixes of stearic acid + cholesteryl oleate (A), 
stearic acid + octadecylamine (B), stearic acid + poloxamer (C), cholesteryl oleate + 
octadecylamine (D), cholesteryl oleate + poloxamer 188 (E) and octadecylamine + 
poloxamer 188 (F). 
Figure 6. Eutectic point graphs of cSLN suspension (A) and cSLN + 5% Trehalose (B). 
Figure 7. cSLNs (lane 1), 500 to 5000 ng of pDNA with (lanes 2-5) or without (lanes 6-
9) cSLNs were loaded on a 0.8% agarose gel. The presence of free DNA in the gel reveals 
 22 
the binding capacity of the nanoparticles. M: Molecular-weight size markers (in kilobase 
pairs) were the DNA ladder digest (New England Biolabs). 
Figure 8. Confocal microscopy images of HeLa cells transfected with Cy3-labeled 
siRNA (A and B) and SLNplexes of Cy3-labeled siRNA:SLNs (panels C and D). Green, 
Alexa Fluor® 488 Staining; red, Cy3-labeled siRNA; blue, DAPI staining. 
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Table 2. Particle size and zeta potential of the SLNs. 












 4 °C 25 °C 
1 187 206 
2 224 227 
3 210 217 
Mean 207 216,67 
Standard Deviation 18,68 10,50 
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Mean 207 34,76 
Standard Deviation 35,06 3,74 
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